Concepedia

Publication | Open Access

Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

286

Citations

21

References

2021

Year

References

YearCitations

Page 1